FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4376638564> ?p ?o ?g. }

• W4376638564 endingPage "106610" @default.
• W4376638564 startingPage "106610" @default.
• W4376638564 abstract "Efforts were directed on the design, synthesis and evaluation of the anticancer activity of some pyrimidine-based hydrazones against two breast cancer cell lines, MCF-7 and MDA-MB-231. Preliminary screening results revealed that some candidates scrutinized for their antiproliferative activities exhibited IC50 values of 0.87 μM–12.91 μM in MCF-7 and 1.75 μM–9.46 μM in MDA-MB-231 cells, indicating almost equal activities on both cell lines and better growth inhibition activities than those of the positive control 5-fluorouracil (5-FU) which displayed IC50 values of 17.02 μM and 11.73 μM respectively. Selectivity of the significantly active compounds was estimated against MCF-10A normal breast cells when compounds 7c, 8b, 9a and 10b exhibited superior activity for cancerous cells than for normal cells when compound 10b presented the best selectivity Index (SI) with respect to both MCF-7 and MDA-MB-231 cancer cells in comparison to the reference drug 5-FU. Mechanisms of their actions were explored by inspecting activation of caspase-9, annexin V staining and cell cycle analysis. It was noticed that compounds 7c, 8b, 8c 9a-c and 10b produced an increase in caspase-9 levels in MCF-7 treated cells with 10b inducing the highest elevation (27.13 ± 0.54 ng/mL) attaining 8.26-fold when compared to control MCF-7 which was higher than that of staurosporine (19.011 ± 0.40 ng/mL). The same compounds boosted caspase-9 levels in MDA-MB-231 treated cells when an increase in caspase-9 concentration reaching 20.40 ± 0.46 ng/mL (4.11-fold increase) was observed for compound 9a. We also investigated the role of these compounds for their increasing apoptosis ability against the 2 cell lines. Compounds 7c, 8b and 10b tested on MCF-7 cells displayed pre-G1 apoptosis and arrested cell cycle in particular at the S and G1 phases. Further clarification of their effects was made by modulating their related activities as inhibitors of ARO and EGFR enzymes when 8c and 9b showed 52.4% and 58.9% inhibition activity relative to letrozole respectively and 9b and 10b showed 36% and 39% inhibition activity of erlotinib. Also, the inhibition activity was verified by docking into the chosen enzymes." @default.
• W4376638564 created "2023-05-17" @default.
• W4376638564 creator A5025007774 @default.
• W4376638564 creator A5036728491 @default.
• W4376638564 creator A5053189150 @default.
• W4376638564 creator A5059134756 @default.
• W4376638564 creator A5076399463 @default.
• W4376638564 creator A5083017921 @default.
• W4376638564 creator A5091624580 @default.
• W4376638564 date "2023-09-01" @default.
• W4376638564 modified "2023-09-30" @default.
• W4376638564 title "Design, synthesis and molecular docking study of new pyrimidine-based hydrazones with selective anti-proliferative activity against MCF-7 and MDA-MB-231 human breast cancer cell lines" @default.
• W4376638564 cites W1496700006 @default.
• W4376638564 cites W1608710587 @default.
• W4376638564 cites W1629179716 @default.
• W4376638564 cites W1994208303 @default.
• W4376638564 cites W2008757142 @default.
• W4376638564 cites W2012312490 @default.
• W4376638564 cites W2018515476 @default.
• W4376638564 cites W2032591736 @default.
• W4376638564 cites W2035948871 @default.
• W4376638564 cites W2044339538 @default.
• W4376638564 cites W2056320914 @default.
• W4376638564 cites W2059417182 @default.
• W4376638564 cites W2076712585 @default.
• W4376638564 cites W2083466846 @default.
• W4376638564 cites W2085444960 @default.
• W4376638564 cites W2099919029 @default.
• W4376638564 cites W2106660927 @default.
• W4376638564 cites W2106788905 @default.
• W4376638564 cites W2114918609 @default.
• W4376638564 cites W2119683782 @default.
• W4376638564 cites W2130743783 @default.
• W4376638564 cites W2140642045 @default.
• W4376638564 cites W2293162408 @default.
• W4376638564 cites W2346235940 @default.
• W4376638564 cites W2402636472 @default.
• W4376638564 cites W2462847503 @default.
• W4376638564 cites W2593357205 @default.
• W4376638564 cites W2594614544 @default.
• W4376638564 cites W2595713273 @default.
• W4376638564 cites W2657253584 @default.
• W4376638564 cites W2767336741 @default.
• W4376638564 cites W2767673340 @default.
• W4376638564 cites W2770595158 @default.
• W4376638564 cites W2792040629 @default.
• W4376638564 cites W2792926295 @default.
• W4376638564 cites W2793671087 @default.
• W4376638564 cites W2796295138 @default.
• W4376638564 cites W2802224675 @default.
• W4376638564 cites W2807500538 @default.
• W4376638564 cites W2890142259 @default.
• W4376638564 cites W2891489835 @default.
• W4376638564 cites W2914589722 @default.
• W4376638564 cites W2919093146 @default.
• W4376638564 cites W2969263349 @default.
• W4376638564 cites W2982449184 @default.
• W4376638564 cites W2995211352 @default.
• W4376638564 cites W2999278164 @default.
• W4376638564 cites W3001847815 @default.
• W4376638564 cites W3004544970 @default.
• W4376638564 cites W3004796255 @default.
• W4376638564 cites W3013638556 @default.
• W4376638564 cites W3025116535 @default.
• W4376638564 cites W3098207268 @default.
• W4376638564 cites W3112064743 @default.
• W4376638564 cites W3128646645 @default.
• W4376638564 cites W3129679768 @default.
• W4376638564 cites W3132887450 @default.
• W4376638564 cites W3139950467 @default.
• W4376638564 cites W3186676943 @default.
• W4376638564 cites W3187806065 @default.
• W4376638564 cites W3204365414 @default.
• W4376638564 cites W4200114335 @default.
• W4376638564 cites W4280596016 @default.
• W4376638564 cites W4281611576 @default.
• W4376638564 cites W4282839173 @default.
• W4376638564 doi "https://doi.org/10.1016/j.bioorg.2023.106610" @default.
• W4376638564 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37210828" @default.
• W4376638564 hasPublicationYear "2023" @default.
• W4376638564 type Work @default.
• W4376638564 citedByCount "1" @default.
• W4376638564 countsByYear W43766385642023 @default.
• W4376638564 crossrefType "journal-article" @default.
• W4376638564 hasAuthorship W4376638564A5025007774 @default.
• W4376638564 hasAuthorship W4376638564A5036728491 @default.
• W4376638564 hasAuthorship W4376638564A5053189150 @default.
• W4376638564 hasAuthorship W4376638564A5059134756 @default.
• W4376638564 hasAuthorship W4376638564A5076399463 @default.
• W4376638564 hasAuthorship W4376638564A5083017921 @default.
• W4376638564 hasAuthorship W4376638564A5091624580 @default.
• W4376638564 hasConcept C109541995 @default.
• W4376638564 hasConcept C121608353 @default.
• W4376638564 hasConcept C126322002 @default.
• W4376638564 hasConcept C159110408 @default.
• W4376638564 hasConcept C184235292 @default.
• W4376638564 hasConcept C185592680 @default.
• W4376638564 hasConcept C190283241 @default.

• next